Ferring Pharmaceuticals
This sponsor has funded 2 studies across 4 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 18906 | Finalised | Observational prospective study describing the global patient care and follow-up of prostate cancer patients treated with Degarelix (DUO study... | Yes | No |
| 38365 | Ongoing | Post-authorisation safety study of NOCDURNA for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria: A multi-country cohort... | No | No |
PAS by Risk Management Plan (RMP) requirement
Ferring Pharmaceuticals
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Ferring Pharmaceuticals
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Ferring Pharmaceuticals
4 Study countries specified are the following:
- Denmark
- France
- Germany
- Sweden